Tumor Organoid Precision Diagnosis and Treatment Service

A personalized testing service using patient-derived organoids to evaluate drug efficacy and identify optimal therapeutic candidates for individual cancer treatment protocols.

A clinical service that provides personalized treatment planning using patient-derived 3D cell culture models. The service leverages cultured patient cells to enable precision medicine approaches in cancer care. It supports clinicians in making informed treatment decisions based on individual patient cell behavior.

Comprehensive precision medicine solutions covering over 2000 service items across oncology, maternal-child health, cardiovascular, and infectious diseases. Services include disease screening, early diagnosis, molecular profiling, drug sensitivity selection, efficacy monitoring, and prognosis assessment.

Comprehensive genetic testing service supporting precision drug therapy and personalized medicine applications. Integrates molecular analysis with therapeutic drug monitoring for comprehensive patient profiling.

Expert pathology and molecular oncology consultation for complex diagnostic cases. Provides second opinions and treatment guidance based on comprehensive genomic analysis.

Comprehensive diagnostic service utilizing liquid biopsy technology for cancer detection, monitoring, and treatment response evaluation. Supports oncologists in selecting optimal cancer medications and detecting drug resistance through frequent, non-invasive blood sampling.

Digital pathology and tissue analysis service for cancer specimen evaluation. Integrates imaging and genomic data for comprehensive diagnosis. Provides expert interpretation and clinical recommendations.

Comprehensive genomic profiling service for tumor samples using advanced sequencing technology. Delivers detailed mutation reports to support clinical decision-making and treatment planning.

Clinical validation and testing services for digital pathology equipment and AI diagnostic tools. Supports market deployment and regulatory compliance for pathology diagnostic solutions.

Precision tumor medication technology service providing engineered cancer kinase-targeted cell libraries and primary cancer cell biobanks for preclinical drug development and tumor precision treatment. Supports oncology research through standardized cell models and bioanalytical services.

Development of patient-derived tumor organoids for therapeutic efficacy testing and precision medicine applications with accurate replication of tumor characteristics.

Three-dimensional organoid culture development from patient tumor samples for personalized drug testing. This approach preserves tumor heterogeneity and enables functional assessment of therapeutic responses.